For patients with multidrug-resistant tuberculosis (TB), taking at least six potentially effective drugs, particularly including pyrazinamide, significantly increased the likelihood of achieving a ...

Multidrug-resistant tuberculosis (MDR-TB) poses a formidable challenge to global health, defined by resistance to at least isoniazid and rifampicin. Traditional treatment regimens are lengthy, toxic ...

Despite global efforts, multidrug-resistant tuberculosis in children is rising at an alarming rate, with younger children at the highest risk of mortality—urgent action is needed to reverse the trend.

An international research team headed by scientists at the University of British Columbia has demonstrated how a novel semi-synthetic compound derived from sanguinarine (SG), an alkaloid extracted ...

Over the last five years, multidrug-resistant (MDR) tuberculosis (TB) cases have been steadily increasing in the country, which is a major public health concern today. patients crafts pandemic, a ...

A clinical trial published in the New England Journal of Medicine showed that the oral antibiotic levofloxacin taken once-daily for six months substantially reduced the risk of developing ...

A new study uncovers vulnerabilities in drug-resistant TB, offering hope for improved treatments. Rutgers Health research has uncovered why a relatively new antibiotic for tuberculosis (TB) works ...

More than 10 million people fall sick with tuberculosis (TB) every year. The disease remains the world’s biggest infectious disease killers with an estimated 1.25 million annual deaths. The disease is ...